← Back to Search

Dietary Supplement

Antioxidant Supplements for Long COVID-19

Phase < 1

Waitlist Available

Research Sponsored by University of California, Irvine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with positive COVID testing (AB, RT PCR) and mild-severe symptoms based on COVID symptom list

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy

Awards & highlights

Study Summary

This trial is testing whether glutathione, N-acetyl cysteine, and alpha lipoic acid can help reverse some of the long-haul symptoms of COVID. Subjects will be randomized to take either a combination of these supplements or the same supplements plus a multivitamin and magnesium. They will be assessed for COVID symptoms, physical and mental health, and will have blood samples taken.

Who is the study for?

This trial is for individuals who have tested positive for COVID-19 and are experiencing mild to severe long-haul symptoms. They must not have allergies or adverse reactions to NAC, ALA, or GSH, no meat product/gelatin allergies (alpha gal allergy), and no history of severe sulfa sensitivity.Check my eligibility

What is being tested?

The study tests if glutathione combined with NAC and ALA can improve long COVID symptoms. Participants will be randomly assigned to receive these supplements with or without a multivitamin and magnesium, while their health status is monitored through questions and blood samples.See study design

What are the potential side effects?

Potential side effects may include allergic reactions in those sensitive to the ingredients used: NAC, ALA, liposomal GSH. Side effects could range from mild digestive discomfort to more serious allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I tested positive for COVID and have symptoms ranging from mild to severe.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ symptoms will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~symptoms will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and symptoms will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC)

COVID Severity of Symptoms Questionnaire

Change in Quality of Life Using SF-36 Survey

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm AExperimental Treatment1 Intervention

Subjects randomized into Group A will take the following amount for 28 days 4 capsules of NAC (600mg each) once in the morning and once in the evening 1 tablet (600mg) of Alamax CR once in the morning and once in the evening 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening

Group II: Arm BActive Control1 Intervention

Subjects randomized into Group B will be taking a multivitamin and magnesium for 14 days. Afterwards, they will take the following for 14 days. 4 capsules of NAC (600mg each) once in the morning and once in the evening 1 tablet (600mg) of Alamax CR once in the morning and once in the evening 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor

544 Previous Clinical Trials

1,922,993 Total Patients Enrolled

Hudson Valley Healing Arts CenterUNKNOWN

Media Library

Alpha lipoic acid (ALA) (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05371288 — Phase < 1

Coronavirus Research Study Groups: Arm B, Arm A

Coronavirus Clinical Trial 2023: Alpha lipoic acid (ALA) Highlights & Side Effects. Trial Name: NCT05371288 — Phase < 1

Alpha lipoic acid (ALA) (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05371288 — Phase < 1

Coronavirus Patient Testimony for trial: Trial Name: NCT05371288 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?

Vermont

What site did they apply to?

University of California Irvine Medical Center

What portion of applicants met pre-screening criteria?

Met criteria

Did not meet criteria

How many prior treatments have patients received?

Why did patients apply to this trial?

I am quite ill and hoping to avoid being diagnosed with ME/CFS. What's a person to do but hope someone will give me treatment (trial).

PatientReceived no prior treatments

I was diagnosed with COVID in August 2022, then was diagnosed with Long COVID (PASC) in September of 2022. I have not gotten better. I've tried h1 & h2 blockers with some benefit, but I have not gotten better. I've been on antibiotics or antifungals or steroids every single month since I got COVID in 2022, but I still cannot work and am disabled from the condition. I'm really interested in NAC & ALA.

PatientReceived 2+ prior treatments